EUCTR2015-003653-17-ES进行中（未招募）1 期
An open label, prospective, randomized, multicenter study investigating clinical efficacy and safety of the human normal immunoglobulin for intravenous administration BT595 in patients with chronic primary immune thrombocytopenia (ITP)
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- Biotest AG
- 入组人数
- 40
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
入选标准
- •a) Written informed consent obtained from subjects indicating that they understand the purpose of and procedures required for the study and are willing to participate
- •b) Male or female, aged 18 through 75 years, inclusive
- •c) Diagnosis of chronic ITP (>12 months’ duration), including diagnosis of refractory ITP, and as defined by the International Working Group (Rodeghiero et al, 2009), where ITP is described as an autoimmune disorder characterized by isolated thrombocytopenia in the absence of other causes or disorders that may be associated with thrombocytopenia
- •d) Treatment is indicated because of a high risk of bleeding or a need to raise the platelet count
- •e) Mean screening platelet count of <30×109/L from 3 qualifying platelet counts performed within approximately 7 to 14 days before the start of treatment, with no individual platelet count above 35×109/L. The subject may be rescreened if the mean screening platelet count is =30×109/L.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 35
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 5
排除标准
- •a) Pregnancy or unreliable contraceptive measures or lactation period (females only)
- •b) Known intolerance to immunoglobulins or comparable substances (e.g., vaccination reaction)
- •c) Known intolerance to proteins of human origin or known allergic reactions to components of the study product
- •d) Participation in another clinical study within 90 days before entering the study or during the study and/or previous participation in this study
- •e) Employee or direct relative of an employee of the contract research organization, the study site, or Biotest
- •f) Secondary thrombocytopenia or acquired medical conditions known to be associated with secondary thrombocytopenia, such as chronic lymphocytic leukemia; lymphoma; multiple myeloma; thyroid disease; or other forms of thrombocytopenia, such as drug induced thrombocytopenia; cirrhotic liver diseases; antiphospholipid syndrome; environmental thrombocytopenia; and bone marrow diseases
- •g) Severe concomitant diseases that in the judgment of the investigator will interfere with the study, such as autoimmune hemolytic anemia, acute renal failure, and noncontrolled arterial hypertension
- •h) Laboratory findings (e.g., abnormal laboratory values for hemoglobin, transaminase levels [alanine aminotransferase, aspartate aminotransferase], total bilirubin, creatinine, blood urea nitrogen, and immunoglobulins G, A, M) that preclude participation
- •i) Positive Coombs test (direct and indirect)
- •j) Planned invasive procedures during the time frame of the study
- •k) Maintenance therapy with intravenous immunoglobulins (IVIgs) or infusion of IVIgs within 3 months before start of the study
- •l) Unresponsive to previous IVIg treatment
- •m) Additional therapy with high dose corticosteroids (equivalent to >30 mg prednisone/day), thrombopoietin receptor agonists, and/or immunosuppressives and/or other therapies (e.g., infusion of platelets) within 1 month before the start of the study (Note: Subjects on stable doses of ITP active treatment must not have modified the dose in the preceding 2 weeks and must maintain their prestudy dose during the study. Corticosteroids should not be given as a premedication. Rescue therapy with short courses [i.e., 1 to 4 days] of high dose steroids and IVIgs are allowed up to 2 weeks before study inclusion.)
- •n) History of thrombotic events (including myocardial infarction, cerebral vascular accident [including stroke], pulmonary embolism, and deep vein thrombosis) 6 months before treatment start with BT595 or the presence of significant risk factors for thrombotic events
- •o) Therapy with live attenuated virus vaccines 3 months before start of the study
- •p) Selective, absolute immunoglobulin A (IgA) deficiency or known antibodies to IgA
研究者
相似试验
进行中（未招募）
1 期
An open label, prospective, randomized, multicenter study investigating clinical efficacy and safety of the human normal immunoglobulin for intravenous administration BT595 in patients with chronic primary immune thrombocytopenia (ITP)EUCTR2015-003653-17-CZBiotest AG34
进行中（未招募）
1 期
An open label, prospective, randomized, multicenter study investigating clinical efficacy and safety of the human normal immunoglobulin for intravenous administration BT595 in patients with chronic primary immune thrombocytopenia (ITP)Chronic primary immune thrombocytopenia (ITP)MedDRA version: 19.0 Level: LLT Classification code 10051057 Term: Idiopathic thrombocytopenia System Organ Class: 100000004851EUCTR2015-003653-17-DEBiotest AG40
进行中（未招募）
1 期
An open label, prospective, randomized, multicenter study investigating clinical efficacy and safety of the human normal immunoglobulin for intravenous administration BT595 in patients with chronic primary immune thrombocytopenia (ITP)EUCTR2015-003653-17-HUBiotest AG40
进行中（未招募）
1 期
An open label, prospective, randomized, multicenter study investigating clinical efficacy and safety of the human normal immunoglobulin for intravenous administration BT595 in patients with chronic primary immune thrombocytopenia (ITP)Chronic primary immune thrombocytopenia (ITP)MedDRA version: 20.0 Level: LLT Classification code 10051057 Term: Idiopathic thrombocytopenia System Organ Class: 100000004851EUCTR2015-003653-17-BGBiotest AG40
进行中（未招募）
1 期
Study of the Safety and Pharmacokinetics of apixaban versus warfarin or low molecular weight heparin in children with congenital or acquired heart disease that need anticoagulatioCongenital or Acquired Heart Disease Requiring Chronic Anticoagulation for Thromboembolism PreventionMedDRA version: 20.0Level: PTClassification code 10019273Term: Heart disease congenitalSystem Organ Class: 10010331 - Congenital, familial and genetic disordersMedDRA version: 20.0Level: PTClassification code 10007636Term: CardiomyopathySystem Organ Class: 10007541 - Cardiac disordersMedDRA version: 20.0Level: LLTClassification code 10019276Term: Heart disease, unspecifiedSystem Organ Class: 10007541 - Cardiac disordersMedDRA version: 21.1Level: PTClassification code 10037400Term: Pulmonary hypertensionSystem Organ Class: 10038738 - Respiratory, thoracic and mediastinal disordersMedDRA version: 20.0Level: PTClassification code 10023320Term: Kawasaki's diseaseSystem Organ Class: 10047065 - Vascular disordersEUCTR2016-001247-39-ATBristol-Myers Squibb International Corporation215